Similarly, another ongoing clinical trial (NCT06100276) evaluates the safety, tolerability, and efficacy of gene therapy AMT-162 in ALS patients with an SOD1 mutation. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.